FTSE 100 today: closes higher as UK inflation surprises; GBP lower, Ithaca report
Paul Kearney, Chief Data Officer at Sera Prognostics Inc. (NASDAQ:SERA), a company whose stock has declined over 54% in the past year, reported a stock sale in a recent SEC filing. According to InvestingPro analysis, SERA currently trades above its Fair Value, with a concerning market cap of $146 million and negative EBITDA of -$35 million. On March 6, Kearney sold 1,338 shares of the company’s Class A Common Stock at an average price of $4.16 per share, totaling approximately $5,566. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by the company’s policy. InvestingPro subscribers can access 8 additional key insights about SERA’s financial health and market position through the comprehensive Pro Research Report.
Additionally, on March 5, Kearney acquired 47,010 shares of Class A Common Stock through restricted stock units, which were granted at no cost. In a separate transaction on the same day, he was granted stock options for 67,810 shares, also at no cost, with an exercise price of $4.20 per share. These options will vest over four years, subject to Kearney’s continued service with the company. While SERA maintains a healthy balance sheet with more cash than debt and a current ratio of 2.11, analysts anticipate continued sales decline and no profitability this year.
In other recent news, Sera Prognostics has announced the termination of its "at-the-market" stock offering, as disclosed in a recent SEC filing. The company had initially planned to sell up to $50 million of its Class A common stock through TD Securities but decided to halt the offering without selling any shares. Meanwhile, Sera Prognostics has also launched a public offering of its Class A common stock and pre-funded warrants, managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets. The proceeds from this offering aim to support U.S. commercial expansion, European Union growth, and FDA approval efforts for its PreTRM test.
Additionally, Sera Prognostics has shared that the Society for Maternal Fetal Medicine has published an abstract on the topline results of its PRIME study. These findings, focusing on neonatal outcomes through prematurity risk assessment, will be discussed in detail at the upcoming SMFM 2025 Pregnancy Meeting. Following this presentation, the company plans a conference call and live audio webcast to delve deeper into the study’s outcomes. These developments highlight Sera Prognostics’ ongoing efforts in research and capital raising to further its mission in maternal and neonatal health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.